AMPH
Amphastar Pharmaceuticals, Inc.Healthcare · $1.2B market cap
Verdict
Share price
$25.43
close of Oct 3, 2026
Fair value
$32.13
Sticker Price
Payback Price
$12.85
buy price
AMPH is Undervalued: at $25.43 it trades 21% below its fair value of $32.13. Its buy price (Payback Price) is $12.85, 49% below today's price. Business quality is strong: 4 of 5 key numbers clear the 10% bar.
How we valued it
Free Cash Flow. Sales grew 13% a year over the last 3 years, below the 15% we look for in a fast grower, so we value it on its free cash flow instead of an earnings forecast.
Business quality
4 of 5 clear the 10% bar. What are the Big Five?
Follow AMPH
Get notified when it reaches its buy price of $12.85. Free.
Create a free accountSuperinvestors
1 of the investors we track holds AMPH. In Q1 2026, 1 trimmed. Who we track
Moves in Q1 2026
Trimmed: Howard Marks
Insider activity
Since Jul 9, 2026: no open-market purchases, 3 sales worth $421K and 3 other filings (stock awards, tax withholding and similar). Why purchases matter
Sales
Zhou Rong
SENIOR EVP, PRODUCTION CENTER · 2026-09-02
Sold
$75K
PRINS RICHARD K
director · 2026-08-11
Sold
$162K
PETERS WILLIAM J
CFO, EVP & TREASURER · 2026-08-07
Sold
$184K
Other filings
About Amphastar Pharmaceuticals, Inc.
Amphastar Pharmaceuticals, Inc., established in 1996 and based in Rancho Cucamonga, California, functions as a biopharmaceutical enterprise. The company is engaged in the creation, production, commercialization, and distribution of both generic and proprietary pharmaceutical products, which include injectables, inhalants, and intranasal formulations. Its market presence extends across the United States, China, and…
Drug Manufacturers - Specialty & Generic
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works